Merus N.V. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
14,671.00
2,227.70
35,686.00
72,528.80
220,612.20
215,600.40
Total Accounts Receivable
1,022.40
674.00
381.30
1,352.20
3,780.10
4,857.20
Other Current Assets
122.60
353.30
1,427.40
1,133.90
1,519.00
3,181.40
Total Current Assets
15,816.10
3,255.00
37,494.70
75,014.90
225,911.30
223,639
Net Property, Plant & Equipment
534.60
427.10
353.00
683.50
1,402.50
2,766.40
Total Investments and Advances
-
-
236.80
176.10
8,477.60
19,370.70
Intangible Assets
768.90
601.40
472.50
394.50
374.70
2,795
Other Assets
-
-
-
-
154.90
1,228.90
Total Assets
17,119.70
4,283.60
38,557.10
76,269.00
236,321.00
249,800
ST Debt & Current Portion LT Debt
230.10
202.10
181.40
176.10
-
Accounts Payable
1,320.10
2,915.00
2,627.80
2,423.80
3,428.30
Other Current Liabilities
3,883.10
3,942.30
4,051.90
5,578.60
19,051.90
Total Current Liabilities
5,433.30
7,059.40
6,861.10
8,178.50
22,480.20
Long-Term Debt
1,128.50
789.00
527.90
336.50
-
Other Liabilities
-
741.80
423.70
31,859.80
156,338.20
Total Liabilities
6,561.80
8,590.10
7,812.70
40,374.80
178,818.30
Common Equity (Total)
10,557.90
4,306.60
30,744.50
35,894.20
57,502.70
Total Shareholders' Equity
10,557.90
4,306.60
30,744.50
35,894.20
57,502.70
Total Equity
10,557.90
4,306.60
30,744.50
35,894.20
57,502.70
Liabilities & Shareholders' Equity
17,119.70
4,283.60
38,557.10
76,269.00
236,321.00

About Merus

View Profile
Address
Yalelaan 62
Utrecht Utrecht 3584 CH
Netherlands
Employees -
Website http://www.merus.nl
Updated 07/08/2019
Merus NV is a clinical-stage immune-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.